MSI2 and acute myeloid leukemia: To determine if the functional demonstration of LSC activity aligned with a molecular LSC signature, we tested whether genes in the previously reported molecular signature of AML LSCs23 were also preferentially enriched in Msi2-reporter+ bcCML cells.